Income Statement Presentation 2023

Ophthalmology: Excellent Vabysmo launch More than 450k vials shipped globally in first 11 months of launch CHFM Q4 update Vabysmo VABYSMO susvim o™ 100mg ml ranibizumab injection Format Roche • US: Strong uptake with switches primarily from aflibercept; use in naive patients further accelerating 350 300 250 200 150 100 50 0 Q122 Q2 22 Q3 22 US Europe International Japan Q4 22 • Rapid launch uptake in UK & Japan • Positive Ph III (BALATON/COMINO) results for Vabysmo in RVO achieved Susvimo • Positive Ph III (PAGODA/PAVILLION) results for Susvimo in DME/DR achieved Outlook 2023 • • Vabysmo: Continued growth and market share gains in nAMD & DME Ph III (MEERKAT/SANDCAT) anti IL-6 mAb in UME started ⚫ Ph Ill results for Vabysmo in RVO and Susvimo in DME/DR to be presented at Angiogenesis (Feb 10-11) DME-diabetic macular edema; RVO-retinal vein occlusion; DR-diabetic retinopathy; UME=uveitic macular edema; mAb-monoclonal antibody; Eylea (aflibercept) is a registered trademark/product of Regeneron 52 32

View entire presentation